310 related articles for article (PubMed ID: 29048983)
41. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
42. The causes and effects of socio-demographic exclusions from clinical trials.
Bartlett C; Doyal L; Ebrahim S; Davey P; Bachmann M; Egger M; Dieppe P
Health Technol Assess; 2005 Oct; 9(38):iii-iv, ix-x, 1-152. PubMed ID: 16181564
[TBL] [Abstract][Full Text] [Related]
43. Meta-analysis of sex and racial subgroup participation rates and differential treatment effects for trials in solid tumor malignancies leading to US Food and Drug Administration registration between 2010 and 2021.
Wilson BE; Nadler MB; Desnoyers A; Booth CM; Amir E
Cancer; 2024 Jan; 130(2):276-286. PubMed ID: 37751315
[TBL] [Abstract][Full Text] [Related]
44. Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot.
Matthew-Onabanjo AN; Nortey G; Matulewicz RS; Basak R; Culton DA; Weaver KN; Gallagher KK; Tan HJ; Rose TL; Milowsky M; Bjurlin MA
Curr Probl Cancer; 2023 Jun; 47(3):100958. PubMed ID: 37084464
[TBL] [Abstract][Full Text] [Related]
45. FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity.
Pulte D; Fernandes L; Wei G; Woods A; Norsworthy KJ; Gormley N; Kanapuru B; Gwise TE; Pazdur R; Schneider J; Theoret MR; Fashoyin-Aje LA; de Claro RA
Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):463-470.e1. PubMed ID: 37076368
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of Diversity of Clinical Trials Informing Health Technology Assessments in the United States: A 5-Year Analysis of Institute for Clinical and Economic Review Assessments.
Agboola F; Wright AC; Herron-Smith S; Mathur D; Rind D
Value Health; 2023 Sep; 26(9):1345-1352. PubMed ID: 37244417
[TBL] [Abstract][Full Text] [Related]
47. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
[TBL] [Abstract][Full Text] [Related]
48. Participation of Older Adults in Clinical Trials for New Drug Applications and Biologics License Applications From 2010 Through 2019.
Lau SWJ; Huang Y; Hsieh J; Wang S; Liu Q; Slattum PW; Schwartz JB; Huang SM; Temple R
JAMA Netw Open; 2022 Oct; 5(10):e2236149. PubMed ID: 36239939
[TBL] [Abstract][Full Text] [Related]
49. Characteristics of race/ethnicity in trials leading to anti-rheumatic drug approval for inflammatory arthritis by the US Food and Drug Administration.
Xie Y; Liu Y; Qin Y; Chen X; Xie Q
Int J Rheum Dis; 2023 Dec; 26(12):2489-2497. PubMed ID: 37854006
[TBL] [Abstract][Full Text] [Related]
50. Minority Representation in Migraine Treatment Trials.
Robbins NM; Bernat JL
Headache; 2017 Mar; 57(3):525-533. PubMed ID: 28127754
[TBL] [Abstract][Full Text] [Related]
51. Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018.
Tanaudommongkon I; John Miyagi S; Green DJ; Burnham JM; van den Anker JN; Park K; Wu J; McCune SK; Yao L; Burckart GJ
Clin Pharmacol Ther; 2020 Nov; 108(5):1018-1025. PubMed ID: 32394430
[TBL] [Abstract][Full Text] [Related]
52. Persistent under-representation of female patients in United States trials of common vascular diseases from 2008 to 2020.
Mayor JM; Preventza O; McGinigle K; Mills JL; Montero-Baker M; Gilani R; Pallister Z; Chung J
J Vasc Surg; 2022 Jan; 75(1):30-36. PubMed ID: 34438003
[TBL] [Abstract][Full Text] [Related]
53. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
54. Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction Act.
Grabowski H; Long G
J Med Econ; 2024; 27(1):463-472. PubMed ID: 38419523
[TBL] [Abstract][Full Text] [Related]
55. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.
Djomand G; Katzman J; di Tommaso D; Hudgens MG; Counts GW; Koblin BA; Sullivan PS
Public Health Rep; 2005; 120(5):543-8. PubMed ID: 16224987
[TBL] [Abstract][Full Text] [Related]
56. Assessment of the approved Risk Evaluation and Mitigation Strategy programs for New Drug Applications and Biologics Licensing Applications.
Johnson NA; Priefer R
Regul Toxicol Pharmacol; 2019 Feb; 101():53-56. PubMed ID: 30473489
[TBL] [Abstract][Full Text] [Related]
57. An overview of Food and Drug Administration regulation of drugs, biologics, and devices to be used for management of periodontal diseases.
Tylenda CA; Weintraub M
Ann Periodontol; 1997 Mar; 2(1):11-7. PubMed ID: 9151539
[TBL] [Abstract][Full Text] [Related]
58. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.
Klonoff DC
J Diabetes Sci Technol; 2020 Mar; 14(2):345-349. PubMed ID: 30862182
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the fragility of pivotal trials used to support US Food and Drug Administration approval for plaque psoriasis.
Shalhout SZ; Bloom R; Drake L; Miller DM
J Am Acad Dermatol; 2021 Feb; 84(2):354-360. PubMed ID: 32320767
[TBL] [Abstract][Full Text] [Related]
60. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities.
Stewart JH; Bertoni AG; Staten JL; Levine EA; Gross CP
Ann Surg Oncol; 2007 Dec; 14(12):3328-34. PubMed ID: 17682824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
